Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
IQ-AI ( (GB:IBAI) ) has shared an update.
Imaging Biometrics Limited has announced a soft close to its Phase 1 clinical trial of oral gallium maltolate for relapsed or refractory glioblastoma, indicating strong early engagement and sufficient enrollment. This milestone allows the company to focus on data consolidation and Phase 2 protocol finalization, with the potential of oral GaM being a transformative agent in glioblastoma care due to its novel mechanism and excellent tolerability. The company is considering independent financing for Phase 2 while exploring strategic partnerships.
More about IQ-AI
Imaging Biometrics Limited, a subsidiary of Imaging Biometrics Limited (LON: IBAI), specializes in quantitative imaging platforms and therapeutics aimed at transforming clinical diagnosis and treatment efficiency and effectiveness.
Average Trading Volume: 516,495
Technical Sentiment Signal: Strong Sell
Current Market Cap: £1.54M
See more data about IBAI stock on TipRanks’ Stock Analysis page.